MedTrace Logo

Drug Interaction Study Between Raltegravir And UK-453,061

NCT00784420 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2008-11-18

No results posted yet for this study

Summary

The purpose of this study is to estimate the effect of steady state raltegravir on the steady state pharmacokinetics of UK-453,061 and steady state UK-453,061 on the steady state pharmacokinetics of raltegravir.

Conditions

  • Healthy Volunteers

Interventions

DRUG

UK-453,061

UK-453,061 1000 mg once daily for 10 days

DRUG

UK-453,061

UK-453,061 1000 mg once daily for 10 days

DRUG

Raltegravir

Raltegravir 400 mg twice daily for 10 days

DRUG

Raltegravir

Raltegravir 400 mg twice daily for 10 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00784420 on ClinicalTrials.gov